Humanitarian Assistance Program

Partnership Objectives

Pfizer will meet humanitarian emergency needs through a short-term donation of the single-dose vial of Prevenar 13®

What are the health needs and challenges?

Accelerating the availability of potentially life-saving vaccines around the world is a key component of Pfizer’s commitment toward global health care access. Delivering vaccines in emergency settings is challenging yet vital in order to meet global health needs. Vaccines require temperature-controlled conditions and adequate storage. As a result, maximising efficiencies in health systems is key.

Description of partnership activities and how they address needs and challenges

In November 2016, Pfizer announced a major expansion of its humanitarian assistance program. Pfizer aims to broaden access to its vaccine, Prevenar 13® in humanitarian emergency settings. The vaccine is used to help protect infants and young children against invasive pneumococcal disease. The vaccine will be offered in its new multi-dose vial at the lowest global price, $3.10 per dose.

In addition, Pfizer will tackle the acute need on the ground by donating all sales proceeds for the first year of the program to humanitarian groups who work on the ground  to reach vulnerable populations.

Starting in 2017, refugees will receive the newest version of Prevenar 13®, the MDV. It contains four doses of Prevenar 13® instead of the current one dose.  This four-in-one vial is designed to address the unique conditions and challenges in developing world settings. The MDV offers reduced cold storage and transportation requirements. It has also been prequalified by the WHO.

Prevenar 13®  was first approved in the European Union and is now used in more than 150 countries worldwide, including the United States, Canada, Australia and Japan.


Partnership information

Company(ies) Pfizer

Therapeutic Focus Vaccine-Preventable Diseases

Disease(s) Meningitis C, Pneumonia

Program Type(s) Availability of Treatment - Product Donations, Prevention Programs - Vaccines

Region(s)

Research Country(ies) Worldwide

Start Date 2016

Anticipated completion date Ongoing